Bevacizumab

TERMINATED · PHASE3 · Retinopathy of Prematurity

Lack of feasibility to recruit.

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.